EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β 1 and is a predictor of outcome in ovarian carcinoma patients

Carcinogenesis

Volumn 31, Issue 9, 2010, Pages 1576-1583

  Rao, Zhi Yue ^a   Cai, Mu Yan ^a   Yang, Guo Fen ^b   He, Li Ru ^a   Mai, Shi Juan ^a   Hua, Wen Feng ^a   Liao, Yi Ji ^a   Deng, Hai Xia ^a   Chen, Yang Chao ^c   Guan, Xin Yuan ^a   Zeng, Yi Xin ^a   Kung, Hsiang Fu ^a,c   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER TISSUE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COHORT ANALYSIS; CYSTADENOMA; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; ONCOGENE; OUTCOME ASSESSMENT; OVARY; OVARY CARCINOMA; OVARY METASTASIS; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RISK FACTOR; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 77956277833     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq150     Document Type: Article

References (37)

1. Runnebaum,I.B. et al. (2001) Epidemiological and molecular aspects of ovarian cancer risk. J. Cancer Res. Clin. Oncol., 127, 73-79.
2. Jemal,A. et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
3. Visintin,I. et al. (2008) Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res., 14, 1065-1072.
4. Schwartz,P.E. (2002) Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat. Res., 107, 99-118.
5. Berchuck,A. et al. (1994) Pathogenesis of ovarian cancers. J. Soc. Gynecol. Investig., 1, 181-190.
6. Hough,C.D. et al. (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res., 60, 6281-6287.
7. Simon,J.A. et al. (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res., 647, 21-29.
8. Varambally,S. et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-629.
9. Kidani,K. et al. (2009) High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol., 45, 39-46.
10. He,L.R. et al. (2010) High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int. J. Cancer, 127, 138-197.
11. Matsukawa,Y. et al. (2006) Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci., 97, 484-491.
12. Mimori,K. et al. (2005) Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur. J. Surg. Oncol., 31, 376-380.
13. Sudo,T. et al. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br. J. Cancer, 92, 1754-1758.
14. Collett,K. et al. (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res., 12, 1168-1174.
15. Bachmann,I.M. et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol., 24, 268-273.
16. Raman,J.D. et al. (2005) Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res., 11, 8570-8576.
17. Chen,Y. et al. (2007) Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology, 46, 200-208.
18. Xie,D. et al. (2003) Heterogeneous expression and association of betacatenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int. J. Cancer, 107, 896-902.
19. Tang,D.J. et al. (2005) Oncogenic transformation by SEI-1 is associated with chromosomal instability. Cancer Res., 65, 6504-6508.
20. Faleiro-Rodrigues,C. et al. (2005) Biological relevance of E-cadherincatenin complex proteins in primary epithelial ovarian tumours. Gynecol. Obstet. Invest., 60, 75-83.
21. Bolat,F. et al. (2010) Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor 1 alpha (HIF-1alpha), and transforming growth factors beta1 (TGFbeta1) and beta3 (TGFbeta3) in gestational trophoblastic disease. Pathol. Res. Pract., 206, 19-23.
22. Jacobs,J.J. et al. (2002) Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim. Biophys. Acta, 1602, 151-161.
23. Cao,R. et al. (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev., 14, 155-164.
24. Visser,H.P. et al. (2001) The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol., 112, 950-958.
25. Kleer,C.G. et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA, 100, 11606-11611.
26. Bracken,A.P. et al. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J., 22, 5323-5335.
27. Croonquist,P.A. et al. (2005) The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene, 24, 6269-6280.
28. Tang,X. et al. (2004) Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene, 23, 5759-5769.
29. Berezovska,O.P. et al. (2006) Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle, 5, 1886-1901.
30. Tan,J. et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev., 21, 1050-1063.
31. Cao,Q. et al. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 27, 7274-7284.
32. Fujii,S. et al. (2008) Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci., 99, 738-746.
33. Higashi,T. et al. (2001) Overexpression of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association with TGF-beta 1 in ovarian carcinoma. Jpn. J. Cancer Res., 92, 506-515.
34. Santin,A.D. et al. (2001) Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG, 108, 804-808.
35. Lin,S.W. et al. (2000) TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin. Exp. Metastasis, 18, 493-499.
36. Do,T.V. et al. (2008) Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-tomesenchymal transition. Mol. Cancer Res., 6, 695-705.
37. Kitagawa,K. et al. (1996) Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-beta1. Int. J. Cancer, 66, 91-97.